Related Experiment Video

Updated: Jun 26, 2025

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.0K

Protein tyrosine phosphatases: emerging role in cancer therapy resistance

Min Zhao1, Wen Shuai1, Zehao Su1,2

  • 1Innovation Center of Nursing Research, Nursing Key Laboratory of Sichuan Province, Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, West China School of Nursing, Sichuan University, Chengdu, Sichuan, P. R. China.

Cancer Communications (London, England)
|May 14, 2024
PubMed
Abstract

Insights

Protein tyrosine phosphatases (PTPs) drive cancer therapy resistance by regulating signaling pathways. Inhibiting PTPs in combination therapy may overcome resistance and promote tumor regression, with clinical trials ongoing.

Area of Science:

  • Molecular Biology
  • Cancer Biology
  • Pharmacology

Background:

  • Tyrosine phosphorylation regulates cellular signaling, with protein tyrosine phosphatases (PTPs) mediating dephosphorylation and pathway cross-talk.
  • PTP-mediated pathways act as signaling hubs in cancer, enabling cells to resist therapy by activating growth pathways or suppressing the immune microenvironment.
  • PTPs are implicated in cancer drug resistance, contributing to treatment failures.

Purpose of the Study:

  • To review recent findings on PTP-mediated pathways in resistance to targeted and immune-checkpoint therapies.
  • To highlight the role of PTPs in cancer cell survival and therapeutic evasion.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of PTP involvement in resistance mechanisms.
  • Synthesis of evidence for PTP inhibition as a therapeutic strategy.

Main Results:

  • PTPs are crucial in developing resistance to targeted and immune-checkpoint therapies.
  • Inhibition of PTPs can reverse drug resistance and enhance anticancer drug efficacy.
  • PTPs modulate tumor microenvironment and promote cancer cell survival under therapy stress.

Conclusions:

  • PTP inhibition represents a promising strategy for anticancer combination therapy.
  • Combining PTP inhibitors with existing treatments may achieve long-term tumor regression.
  • Clinical trials are evaluating the safety and efficacy of PTP inhibition in advanced cancers.
Keywords:
cancer treatmentcombination therapydrug resistanceprotein tyrosine phosphatase

More Related Videos

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.2K
Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases06:56

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases

Published on: September 6, 2024

358

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
13.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.4K